Benefit-Risk Assessment of Atypical Antipsychotics in the Treatment of Schizophrenia and Comorbid Disorders in Children and Adolescents

Author： Paz Toren Sharon Ratner Nathaniel Laor Abraham Weizman

Publisher： Adis International

ISSN： 0114-5916

Source： Drug Safety, Vol.27, Iss.14, 2004-01, pp. : 1135-1156

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Risk-Benefit Assessment of Pharmacotherapy for Anxiety Disorders in Children and Adolescents

By Hawkridge S.M. Stein D.J.

Drug Safety, Vol. 19, Iss. 4, 1998-10 ,pp. : 283-297

Adis International

Access to resources Recommend Favorite

Antipsychotics for schizophrenia in children and adolescents

Inpharma, Vol. 1, Iss. 1303, 2001-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Modifying the risk of atypical antipsychotics in the treatment of juvenile-onset schizophrenia

By Townsend Lisa Findling Robert L

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 2, 2010-02 ,pp. : 195-205

Informa Healthcare

Access to resources Recommend Favorite

Benefit-Risk Assessment of Bevacizumab in the Treatment of Breast Cancer

By Dienstmann Rodrigo

Drug Safety, Vol. 35, Iss. 1, 2012-01 ,pp. : 15-25

Adis International

Access to resources Recommend Favorite

Benefit-Risk Assessment of Levetiracetam in the Treatment of Partial Seizures

By Abou-Khalil Bassel

Drug Safety, Vol. 28, Iss. 10, 2005-01 ,pp. : 871-890

Adis International

Access to resources Recommend Favorite